Overall, the median time from biopsy to treatment was 35 days, but differed significantly between patients whose diagnosis ...

Until prospective data are available, researchers recommend that patients with ER-low breast cancer “should be counseled regarding the potential benefit” of adjuvant endocrine therapy.

A prognostic index can be used to identify patients with estrogen receptor (ER)-positive, HER2-negative early breast cancer who can safely forgo adjuvant chemotherapy as well as patients who require ...

Standard of care for early ER-positive breast cancer includes 5-10 years of adjuvant endocrine therapy, which has been shown to reduce recurrence, decrease breast cancer mortality, and improve OS ...

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on May 5, 2025, the Compensation ...

NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult ...

IceCure announced it concluded a meeting with the FDA's Center for Devices and Radiological Health regarding the Company's De Novo marketing authorization request for ProSense® in the treatment ...